Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.47 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.79 |
| ▸ | NPC1 | O15118 | 6/20 | 0.79 |
| ▸ | RAB9A | P51151 | 6/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | RAD52 | P43351 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | RGS12 | O14924 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL636714 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| Hydrochloric Acid SCHEMBL30980102 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| Hydrochloric Acid SCHEMBL330337 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| Hydrochloric Acid SCHEMBL635996 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| Hydrochloric Acid SCHEMBL330172 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| Hydrochloric Acid SCHEMBL2530562 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| SCHEMBL627771 | 0.98 | SMN1; SMN2 (0.81) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| SCHEMBL4070988 | 0.98 | SMN1; SMN2 (0.81) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| Hydrochloric Acid SCHEMBL9358066 | 0.98 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9APOLBHTT | |
| SCHEMBL627732 | 0.98 | SMN1; SMN2 (0.81) | SMN1; SMN2NPC1RAB9APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115138857-A | Nano silver particles, preparation method and application thereof | 四川省伊洁士医疗科技有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-20260092048-A1 | SOLID FORMS AND SALTS OF A QUINOLINE CGAS ANTAGONIST COMPOUND | IMMUNESENSOR THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3880266-B1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING ON MODIFIED DEVICE SURFACE | LUTONIX INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| US-20250115564-A1 | cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486734-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119137112-A | Quinoline cGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240400513-A1 | NOVEL COMPOUNDS | UCL BUSINESS LTD (GB) | 2024-12-05 | — | — | US | disclosed |
| US-6306810-B1 | GERMICIDAL CATIONIC AND FILM-FORMING ORGANOSILICONE QUATERNARY AMMONIUM SURFACTANTS; SANITATION | RECKITT BENCKISER INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1104451-A1 | ACIDIC HARD SURFACE CLEANING AND DISINFECTING COMPOSITIONS | Reckitt Benckiser Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1104452-A1 | ALKALINE HARD SURFACE CLEANING AND DISINFECTING COMPOSITIONS | Reckitt Benckiser Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| US-6136770-A | COMPRISING CATIONIC SURFACTANT, FLUOROSURFACTANT, FILM-FORMING ORGANOSILICONE QUARTENARY AMMONIUM COMPOUND, WATER | RECKITT BENCKISER INC. (US) | 2000-10-24 | — | — | US | disclosed |
| WO-2000009643-A1 | ACIDIC HARD SURFACE CLEANING AND DISINFECTING COMPOSITIONS | RECKITT BENCKISER INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009644-A1 | ALKALINE HARD SURFACE CLEANING AND DISINFECTING COMPOSITIONS | RECKITT BENCKISER INC (US) | 2000-02-24 | — | — | WO | disclosed |
| US-5164194-A | Treatment of irritated eye and nose mucous membranes resulting from a cold or allergy | ASTA PHARMA AG (DE) | 1992-11-17 | — | — | US | disclosed |
| US-4435329-A | ANTIHYPERTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-RE30874-E | IN COMBINATION WITH N-ETHANOLACETAMIDE AND POLYETHYLENIMINES | ALBERTO-CULVER COMPANY (US) | 1982-03-02 | — | — | US | disclosed |
| US-3980091-A | Quaternary ammonium compounds in pretreatment of hair before shampooing with an anionic shampoo | ALBERTO CULVER COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CHRM2 611/4885CHRM1 767/4885ACHE 849/4885 |
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, SSB, NT5C2 | CHRM2 784/4885CHRM1 1173/4885ACHE 4260/4885 |
| US-20250115564-A1 | cGAS ANTAGONIST COMPOUNDS | CGAS, STING1, GLS2 | CHRM2 548/4885CHRM1 768/4885ACHE 1723/4885 |
| US-20240400513-A1 | NOVEL COMPOUNDS | SERPINC1, SERPINA2, SERPINA3 | CHRM2 2453/4885CHRM1 1408/4885ACHE 835/4885 |
| US-20260092048-A1 | SOLID FORMS AND SALTS OF A QUINOLINE CGAS ANTAGONIST COMPOUND | STING1, CGAS, TBK1 | CHRM2 1522/4885CHRM1 1311/4885ACHE 2006/4885 |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CHRM2 611/4885CHRM1 767/4885ACHE 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.